A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease

Patients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tariq Ahmad, Ralph J Riello, Silvio E Inzucchi
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/5a91fa8d33ae45ea8b5afd48cb104e34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a91fa8d33ae45ea8b5afd48cb104e34
record_format	dspace
spelling	oai:doaj.org-article:5a91fa8d33ae45ea8b5afd48cb104e342021-12-04T16:04:09ZA Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease10.15420/ecr.2020.01.R11758-37641758-3756https://doaj.org/article/5a91fa8d33ae45ea8b5afd48cb104e342021-03-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.01.R1https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Patients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categories of diabetes medications, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been associated with improved rates of major adverse cardiovascular events when used in high-risk type 2 diabetes patients. Importantly, these effects are not necessarily linked to these agents’ effects on HbA1c. Sodium–glucose cotransporter 2 inhibitors have also been associated with reductions in heart failure hospitalization, a benefit that appears to extend to individuals without diabetes with established heart failure. Cardiovascular specialists should become familiar with these emerging data and be prepared to implement corresponding strategies in their practice to improve the cardiovascular outcomes of their patients. Recent clinical trial data and the changing landscape of corresponding professional guidelines are reviewed. Practical recommendations for safe prescribing of these anti-diabetes drugs are provided.Tariq AhmadRalph J RielloSilvio E InzucchiRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Tariq Ahmad Ralph J Riello Silvio E Inzucchi A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
description	Patients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categories of diabetes medications, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been associated with improved rates of major adverse cardiovascular events when used in high-risk type 2 diabetes patients. Importantly, these effects are not necessarily linked to these agents’ effects on HbA1c. Sodium–glucose cotransporter 2 inhibitors have also been associated with reductions in heart failure hospitalization, a benefit that appears to extend to individuals without diabetes with established heart failure. Cardiovascular specialists should become familiar with these emerging data and be prepared to implement corresponding strategies in their practice to improve the cardiovascular outcomes of their patients. Recent clinical trial data and the changing landscape of corresponding professional guidelines are reviewed. Practical recommendations for safe prescribing of these anti-diabetes drugs are provided.
format	article
author	Tariq Ahmad Ralph J Riello Silvio E Inzucchi
author_facet	Tariq Ahmad Ralph J Riello Silvio E Inzucchi
author_sort	Tariq Ahmad
title	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
title_short	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
title_full	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
title_fullStr	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
title_full_unstemmed	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
title_sort	practical guide for cardiologists to the pharmacological treatment of patients with type 2 diabetes and cardiovascular disease
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/5a91fa8d33ae45ea8b5afd48cb104e34
work_keys_str_mv	AT tariqahmad apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT ralphjriello apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT silvioeinzucchi apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT tariqahmad practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT ralphjriello practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT silvioeinzucchi practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease
_version_	1718372674496888832

A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease

Ejemplares similares